Gyre Therapeutics (GYRE) Return on Sales (2016 - 2025)
Historic Return on Sales for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to 0.19%.
- Gyre Therapeutics' Return on Sales rose 800.0% to 0.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.1%, marking a year-over-year increase of 9100.0%. This contributed to the annual value of 0.16% for FY2024, which is 9200.0% up from last year.
- According to the latest figures from Q3 2025, Gyre Therapeutics' Return on Sales is 0.19%, which was up 800.0% from 0.06% recorded in Q2 2025.
- Over the past 5 years, Gyre Therapeutics' Return on Sales peaked at 3.68% during Q3 2022, and registered a low of 18.31% during Q1 2022.
- In the last 5 years, Gyre Therapeutics' Return on Sales had a median value of 0.06% in 2025 and averaged 3.73%.
- Per our database at Business Quant, Gyre Therapeutics' Return on Sales tumbled by -150400bps in 2021 and then soared by 184800bps in 2023.
- Quarter analysis of 5 years shows Gyre Therapeutics' Return on Sales stood at 8.32% in 2021, then soared by 97bps to 0.28% in 2022, then crashed by -1222bps to 3.75% in 2023, then skyrocketed by 100bps to 0.02% in 2024, then surged by 1350bps to 0.19% in 2025.
- Its Return on Sales was 0.19% in Q3 2025, compared to 0.06% in Q2 2025 and 0.17% in Q1 2025.